The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Meningococcal Vaccine Market Research Report 2024
Synopsis
Meningococcal vaccine refers to any of the vaccines used to prevent infection by Neisseria meningitides. The vaccines are between 85 and 100% effective for at least two years. They result in a decrease in meningitis and sepsis among populations where they are widely used. They are given either by injection into a muscle or just under the skin.
The global Meningococcal Vaccine market was valued at US$ 262 million in 2023 and is anticipated to reach US$ 355.4 million by 2030, witnessing a CAGR of 4.4% during the forecast period 2024-2030.
Global Meningococcal Vaccine key players include GSK, SANOFI PASTEUR S.A, Norvatis, Crucell, Medimmune, etc. Global top five players hold a share about 80%.
Europe is the largest market, with a share about 45%, followed by North America and China, having a total share about 40 percent.
In terms of product, Polysaccharide Meningtitis AC is the largest segment, with a share about 95%. And in terms of application, the largest application is 6 Months-15Year, followed by over 3 Year, over 2 Year, over 3 Months.
This report aims to provide a comprehensive presentation of the global market for Meningococcal Vaccine, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Meningococcal Vaccine.
Report Scope
The Meningococcal Vaccine market size, estimations, and forecasts are provided in terms of sales volume (10K Pcs) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Meningococcal Vaccine market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Meningococcal Vaccine manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Novartis
GSK
Merck
CSL
Baxter
JN International Medical Corporation
Serum Institute of India
Bio-Med
China National Biotec Group
Hualan Bio
Walvax
Zhifei
Segment by Type
Meningtits A
Polysaccharide Meningtitis AC
Meningitis ACYW
Segment by Application
6 Months-15Year
over 3 Year
over 2 Year
over 3 Months
Consumption by Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Meningococcal Vaccine manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Meningococcal Vaccine in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
Meningococcal vaccine refers to any of the vaccines used to prevent infection by Neisseria meningitides. The vaccines are between 85 and 100% effective for at least two years. They result in a decrease in meningitis and sepsis among populations where they are widely used. They are given either by injection into a muscle or just under the skin.
The global Meningococcal Vaccine market was valued at US$ 262 million in 2023 and is anticipated to reach US$ 355.4 million by 2030, witnessing a CAGR of 4.4% during the forecast period 2024-2030.
Global Meningococcal Vaccine key players include GSK, SANOFI PASTEUR S.A, Norvatis, Crucell, Medimmune, etc. Global top five players hold a share about 80%.
Europe is the largest market, with a share about 45%, followed by North America and China, having a total share about 40 percent.
In terms of product, Polysaccharide Meningtitis AC is the largest segment, with a share about 95%. And in terms of application, the largest application is 6 Months-15Year, followed by over 3 Year, over 2 Year, over 3 Months.
This report aims to provide a comprehensive presentation of the global market for Meningococcal Vaccine, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Meningococcal Vaccine.
Report Scope
The Meningococcal Vaccine market size, estimations, and forecasts are provided in terms of sales volume (10K Pcs) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Meningococcal Vaccine market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Meningococcal Vaccine manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Novartis
GSK
Merck
CSL
Baxter
JN International Medical Corporation
Serum Institute of India
Bio-Med
China National Biotec Group
Hualan Bio
Walvax
Zhifei
Segment by Type
Meningtits A
Polysaccharide Meningtitis AC
Meningitis ACYW
Segment by Application
6 Months-15Year
over 3 Year
over 2 Year
over 3 Months
Consumption by Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Meningococcal Vaccine manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Meningococcal Vaccine in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
Index1 Meningococcal Vaccine Market Overview
1.1 Product Overview and Scope of Meningococcal Vaccine
1.2 Meningococcal Vaccine Segment by Type
1.2.1 Global Meningococcal Vaccine Market Value Comparison by Type (2024-2030)
1.2.2 Meningtits A
1.2.3 Polysaccharide Meningtitis AC
1.2.4 Meningitis ACYW
1.3 Meningococcal Vaccine Segment by Application
1.3.1 Global Meningococcal Vaccine Market Value by Application: (2024-2030)
1.3.2 6 Months-15Year
1.3.3 over 3 Year
1.3.4 over 2 Year
1.3.5 over 3 Months
1.4 Global Meningococcal Vaccine Market Size Estimates and Forecasts
1.4.1 Global Meningococcal Vaccine Revenue 2019-2030
1.4.2 Global Meningococcal Vaccine Sales 2019-2030
1.4.3 Global Meningococcal Vaccine Market Average Price (2019-2030)
1.5 Assumptions and Limitations
2 Meningococcal Vaccine Market Competition by Manufacturers
2.1 Global Meningococcal Vaccine Sales Market Share by Manufacturers (2019-2024)
2.2 Global Meningococcal Vaccine Revenue Market Share by Manufacturers (2019-2024)
2.3 Global Meningococcal Vaccine Average Price by Manufacturers (2019-2024)
2.4 Global Meningococcal Vaccine Industry Ranking 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Meningococcal Vaccine, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Meningococcal Vaccine, Product Type & Application
2.7 Meningococcal Vaccine Market Competitive Situation and Trends
2.7.1 Meningococcal Vaccine Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Meningococcal Vaccine Players Market Share by Revenue
2.7.3 Global Meningococcal Vaccine Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Meningococcal Vaccine Retrospective Market Scenario by Region
3.1 Global Meningococcal Vaccine Market Size by Region: 2019 Versus 2023 Versus 2030
3.2 Global Meningococcal Vaccine Global Meningococcal Vaccine Sales by Region: 2019-2030
3.2.1 Global Meningococcal Vaccine Sales by Region: 2019-2024
3.2.2 Global Meningococcal Vaccine Sales by Region: 2025-2030
3.3 Global Meningococcal Vaccine Global Meningococcal Vaccine Revenue by Region: 2019-2030
3.3.1 Global Meningococcal Vaccine Revenue by Region: 2019-2024
3.3.2 Global Meningococcal Vaccine Revenue by Region: 2025-2030
3.4 North America Meningococcal Vaccine Market Facts & Figures by Country
3.4.1 North America Meningococcal Vaccine Market Size by Country: 2019 VS 2023 VS 2030
3.4.2 North America Meningococcal Vaccine Sales by Country (2019-2030)
3.4.3 North America Meningococcal Vaccine Revenue by Country (2019-2030)
3.4.4 U.S.
3.4.5 Canada
3.5 Europe Meningococcal Vaccine Market Facts & Figures by Country
3.5.1 Europe Meningococcal Vaccine Market Size by Country: 2019 VS 2023 VS 2030
3.5.2 Europe Meningococcal Vaccine Sales by Country (2019-2030)
3.5.3 Europe Meningococcal Vaccine Revenue by Country (2019-2030)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Meningococcal Vaccine Market Facts & Figures by Country
3.6.1 Asia Pacific Meningococcal Vaccine Market Size by Country: 2019 VS 2023 VS 2030
3.6.2 Asia Pacific Meningococcal Vaccine Sales by Country (2019-2030)
3.6.3 Asia Pacific Meningococcal Vaccine Revenue by Country (2019-2030)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.7 Latin America Meningococcal Vaccine Market Facts & Figures by Country
3.7.1 Latin America Meningococcal Vaccine Market Size by Country: 2019 VS 2023 VS 2030
3.7.2 Latin America Meningococcal Vaccine Sales by Country (2019-2030)
3.7.3 Latin America Meningococcal Vaccine Revenue by Country (2019-2030)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Meningococcal Vaccine Market Facts & Figures by Country
3.8.1 Middle East and Africa Meningococcal Vaccine Market Size by Country: 2019 VS 2023 VS 2030
3.8.2 Middle East and Africa Meningococcal Vaccine Sales by Country (2019-2030)
3.8.3 Middle East and Africa Meningococcal Vaccine Revenue by Country (2019-2030)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Meningococcal Vaccine Sales by Type (2019-2030)
4.1.1 Global Meningococcal Vaccine Sales by Type (2019-2024)
4.1.2 Global Meningococcal Vaccine Sales by Type (2025-2030)
4.1.3 Global Meningococcal Vaccine Sales Market Share by Type (2019-2030)
4.2 Global Meningococcal Vaccine Revenue by Type (2019-2030)
4.2.1 Global Meningococcal Vaccine Revenue by Type (2019-2024)
4.2.2 Global Meningococcal Vaccine Revenue by Type (2025-2030)
4.2.3 Global Meningococcal Vaccine Revenue Market Share by Type (2019-2030)
4.3 Global Meningococcal Vaccine Price by Type (2019-2030)
5 Segment by Application
5.1 Global Meningococcal Vaccine Sales by Application (2019-2030)
5.1.1 Global Meningococcal Vaccine Sales by Application (2019-2024)
5.1.2 Global Meningococcal Vaccine Sales by Application (2025-2030)
5.1.3 Global Meningococcal Vaccine Sales Market Share by Application (2019-2030)
5.2 Global Meningococcal Vaccine Revenue by Application (2019-2030)
5.2.1 Global Meningococcal Vaccine Revenue by Application (2019-2024)
5.2.2 Global Meningococcal Vaccine Revenue by Application (2025-2030)
5.2.3 Global Meningococcal Vaccine Revenue Market Share by Application (2019-2030)
5.3 Global Meningococcal Vaccine Price by Application (2019-2030)
6 Key Companies Profiled
6.1 Novartis
6.1.1 Novartis Corporation Information
6.1.2 Novartis Description and Business Overview
6.1.3 Novartis Meningococcal Vaccine Sales, Revenue and Gross Margin (2019-2024)
6.1.4 Novartis Meningococcal Vaccine Product Portfolio
6.1.5 Novartis Recent Developments/Updates
6.2 GSK
6.2.1 GSK Corporation Information
6.2.2 GSK Description and Business Overview
6.2.3 GSK Meningococcal Vaccine Sales, Revenue and Gross Margin (2019-2024)
6.2.4 GSK Meningococcal Vaccine Product Portfolio
6.2.5 GSK Recent Developments/Updates
6.3 Merck
6.3.1 Merck Corporation Information
6.3.2 Merck Description and Business Overview
6.3.3 Merck Meningococcal Vaccine Sales, Revenue and Gross Margin (2019-2024)
6.3.4 Merck Meningococcal Vaccine Product Portfolio
6.3.5 Merck Recent Developments/Updates
6.4 CSL
6.4.1 CSL Corporation Information
6.4.2 CSL Description and Business Overview
6.4.3 CSL Meningococcal Vaccine Sales, Revenue and Gross Margin (2019-2024)
6.4.4 CSL Meningococcal Vaccine Product Portfolio
6.4.5 CSL Recent Developments/Updates
6.5 Baxter
6.5.1 Baxter Corporation Information
6.5.2 Baxter Description and Business Overview
6.5.3 Baxter Meningococcal Vaccine Sales, Revenue and Gross Margin (2019-2024)
6.5.4 Baxter Meningococcal Vaccine Product Portfolio
6.5.5 Baxter Recent Developments/Updates
6.6 JN International Medical Corporation
6.6.1 JN International Medical Corporation Corporation Information
6.6.2 JN International Medical Corporation Description and Business Overview
6.6.3 JN International Medical Corporation Meningococcal Vaccine Sales, Revenue and Gross Margin (2019-2024)
6.6.4 JN International Medical Corporation Meningococcal Vaccine Product Portfolio
6.6.5 JN International Medical Corporation Recent Developments/Updates
6.7 Serum Institute of India
6.6.1 Serum Institute of India Corporation Information
6.6.2 Serum Institute of India Description and Business Overview
6.6.3 Serum Institute of India Meningococcal Vaccine Sales, Revenue and Gross Margin (2019-2024)
6.4.4 Serum Institute of India Meningococcal Vaccine Product Portfolio
6.7.5 Serum Institute of India Recent Developments/Updates
6.8 Bio-Med
6.8.1 Bio-Med Corporation Information
6.8.2 Bio-Med Description and Business Overview
6.8.3 Bio-Med Meningococcal Vaccine Sales, Revenue and Gross Margin (2019-2024)
6.8.4 Bio-Med Meningococcal Vaccine Product Portfolio
6.8.5 Bio-Med Recent Developments/Updates
6.9 China National Biotec Group
6.9.1 China National Biotec Group Corporation Information
6.9.2 China National Biotec Group Description and Business Overview
6.9.3 China National Biotec Group Meningococcal Vaccine Sales, Revenue and Gross Margin (2019-2024)
6.9.4 China National Biotec Group Meningococcal Vaccine Product Portfolio
6.9.5 China National Biotec Group Recent Developments/Updates
6.10 Hualan Bio
6.10.1 Hualan Bio Corporation Information
6.10.2 Hualan Bio Description and Business Overview
6.10.3 Hualan Bio Meningococcal Vaccine Sales, Revenue and Gross Margin (2019-2024)
6.10.4 Hualan Bio Meningococcal Vaccine Product Portfolio
6.10.5 Hualan Bio Recent Developments/Updates
6.11 Walvax
6.11.1 Walvax Corporation Information
6.11.2 Walvax Meningococcal Vaccine Description and Business Overview
6.11.3 Walvax Meningococcal Vaccine Sales, Revenue and Gross Margin (2019-2024)
6.11.4 Walvax Meningococcal Vaccine Product Portfolio
6.11.5 Walvax Recent Developments/Updates
6.12 Zhifei
6.12.1 Zhifei Corporation Information
6.12.2 Zhifei Meningococcal Vaccine Description and Business Overview
6.12.3 Zhifei Meningococcal Vaccine Sales, Revenue and Gross Margin (2019-2024)
6.12.4 Zhifei Meningococcal Vaccine Product Portfolio
6.12.5 Zhifei Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Meningococcal Vaccine Industry Chain Analysis
7.2 Meningococcal Vaccine Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Meningococcal Vaccine Production Mode & Process
7.4 Meningococcal Vaccine Sales and Marketing
7.4.1 Meningococcal Vaccine Sales Channels
7.4.2 Meningococcal Vaccine Distributors
7.5 Meningococcal Vaccine Customers
8 Meningococcal Vaccine Market Dynamics
8.1 Meningococcal Vaccine Industry Trends
8.2 Meningococcal Vaccine Market Drivers
8.3 Meningococcal Vaccine Market Challenges
8.4 Meningococcal Vaccine Market Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
